Research efforts aiming at neuroimaging-aided differential diagnosis for psychiatric disorders have been progressing rapidly. A previous multisite study has developed a supplementary diagnostic system using functional near-infrared spectroscopy (fNIRS) that can be easily applied to clinical settings. However, few neuroimaging biomarkers have been developed for the psychosis spectrum with various clinical stages.
S
CHIZOPHRENIA IS A syndrome that consists of psychotic and negative symptoms, as well as cognitive deficits. 1, 2 Dysfunction in the prefrontal cortex (PFC) is thought to be associated with these symptoms. Previous studies on first-episode psychosis (FEP) and ultra-high risk for psychosis (UHR) have suggested that neurobiological alterations emerge even before the onset of psychosis, 3, 4 while, not being mutually exclusive, others progressively emerge within a few years from the onset of schizophrenia. 5, 6 Magnetic resonance imaging (MRI) studies have recently shown that brain volume can reflect present clinical stage and predict transition to psychosis. 3, 7 However, brain volume and function develop and change throughout life, especially in the PFC, which undergoes a growth spurt through late adolescence and early adulthood, 8, 9 which is also a peak period for the onset of psychosis. 10 In addition, brain volume and function and their development differ by sex, and these differences clearly appear in the beginning of adolescence. 11 These results suggest that neuroimaging tools should consider age and sex for application to clinical use.
Functional near-infrared spectroscopy (fNIRS) is a promising candidate tool for supplementary examination for differential diagnosis and clinical evaluation in clinical settings. fNIRS indirectly measures blood hemoglobin changes, which are thought to partly reflect regional brain activity, in the surface of the cortex using near-infrared light (650-1000 nm) emitted from a source probe on the human scalp; part of this light is absorbed by hemoglobin in small vessels (<1 mm). 12, 13 A detector probe, normally placed 3 cm away from the source probe in adults, can detect scattered near-infrared light that is reflected back. Using modified Beer-Lambert law, relative hemoglobin concentration can be calculated from the difference between estimated and detected intensity of near-infrared light at a detector probe. The relative advantages of fNIRS technology are as follows: (i) the instrument is small and can easily be taken to places such as schools and care units; (ii) the instrument generates little noise; and (iii) the procedure provides the ability to easily and non-invasively measure hemoglobin changes over the surface of the cortex. 12 Compared to functional MRI, fNIRS is able to measure hemodynamic response with high temporal resolution and a nonrestricted position. Previous fNIRS studies using a 60-s continuous verbal fluency as a cognitive activation task have demonstrated that Japanese 12, [14] [15] [16] [17] [18] and Chinese 19, 20 patients with chronic schizophrenia (ChSZ) exhibited smaller and more delayed activity in the PFC compared to healthy controls (HC). In contrast, patients with major depressive disorder (MDD) showed similarly smaller-thannormal activation, but instead had normally timed activity. 15, 18 In contrast to most MRI studies that intend to differentiate between patients and HC, these fNIRS studies suggest that the overall change of the brain activity throughout the task could differentiate between ChSZ and MDD. To utilize the strengths of fNIRS and the cognitive task, whose findings are easier to replicate than those of MRI studies, a recent multicenter study with more than 1000 participants (153 MDD patients, 136 ChSZ patients, 134 bipolar disorder [BD] patients with depressive symptoms, and 590 HC) developed an fNIRS as a clinical examination device for general practice. 21 In this system, simplified variables, including the intensity (Integral value) and the timing (Centroid value) of prefrontal activity during the task were used as diagnostic predictors. The results showed that the Integral value could discriminate between patients and HC with more than 70% accuracy, and the Centroid value could differentiate between psychosis spectrum disorders (i.e., schizophrenia and BD) and MDD with more than 80% accuracy. 21 In particular, there were few biomarkers that could differentiate the two patient groups except for the Centroid value. On the other hand, the Integral value has less importance as a biomarker for clinical assessment compared to the Centroid value. In 2014, the Ministry of Health, Labour, and Welfare of Japan approved this system as a clinically supplemental diagnostic tool to differentiate between psychotic disorders and MDD in qualified medical institutes by public health insurance. 12 However, some researchers were critical of this decision and suggested that approval of this system by public health insurance without solid scientific evidence was premature. 22 Most of the participants in this previous study were, however, middle-aged, medicated, and in the chronic stage, and were measured cross-sectionally. 21 Our recent studies have suggested that the activity in the PFC as measured by fNIRS is altered by age 23 and the clinical stages of psychotic disorders. 24 For example, greater activity in the rostral PFC is associated with better functional outcome in FEP.
14 Expanding the application of fNIRS-aided systems to the broader psychosis spectrum could help differential diagnosis and allow early intervention and appropriate care.
The first aim of the present study was to test whether the result from the previous investigation, that patients with ChSZ could be successfully classified to the psychosis spectrum group from the MDD group using the Centroid value, is reproducible. We also intended to explore whether the patients could be classified to the patient group from the HC using the Integral value. If the discrimination by the original equation did not reach a satisfactory level of replication, we improved the calculation method, taking age and sex into consideration. The second and main purpose of our study was to test whether the modified Centroid and Integral values could be applicable to various clinical stages, including UHR and FEP. Finally, our third purpose was to test whether accuracy could be replicated in 12-month longitudinal measurements for the UHR, FEP, and HC groups. We hypothesized that the participants in the UHR, FEP, and ChSZ groups would be successfully classified to the patient group using the modified Integral value and to the psychosis spectrum group using the modified Centroid value.
METHODS

Study setting and participants
A total of 144 participants -47 UHR individuals (18 drug-naïve), 30 patients with FEP (six drugnaïve), 34 patients with ChSZ (one drug-naïve), and 33 HC -were included in the first and second hypotheses of this study (Table S1 ). HC were matched for sex and premorbid IQ to the other groups, and for age to the FEP and ChSZ groups. The FEP patients, ChSZ patients, and HC were recruited from July 2009 to June 2014, independently of the previous study. 21 For the third hypothesis, we measured hemodynamic response using the same fNIRS procedure at 12 months after the baseline measurement in 34 UHR individuals (72%), 21 patients with FEP (70%), and 33 HC (mean days AE SD: UHR, 352 AE 134; FEP, 335 AE 131; HC, 409 AE 160; P > 0.05; Table S3 ). Demographic variables at baseline were not significantly different between followed and unfollowed participants, except for the Global Assessment of Functioning (GAF) scores in the UHR group (48.2 AE 10.5 vs 41.2 AE 8.5, respectively, P = 0.034). Six UHR individuals (6/34, 17.6%) had transited to psychosis by the 12-month follow up.
The study participants in the UHR and FEP groups were recruited as a part of the Integrative Neuroimaging Studies in Schizophrenia Targeting for Early Intervention and Prevention (IN-STEP) research project, and the whole research setting has been described in detail elsewhere. 25 Participants were recruited from the outpatient and inpatient units of the University of Tokyo Hospital, the University of Tokyo Health Service Center, psychiatry clinics, and Internet referrals. The inclusion criteria were age 15-30 years for the UHR group and 15-40 years for the other groups. The UHR and FEP participants had had no antipsychotic medication for more than 16 cumulative weeks, and no continuous psychotic symptoms within the past 60 months. All eligible participants were assessed using the Structured Interview for Prodromal Symptoms for the UHR group (File S1), 26, 27 and the DSM-IV for the FEP and ChSZ groups. 28 In the ChSZ group, we recruited participants from the outpatient and inpatient units of the University of Tokyo Hospital. All clinical assessments were conducted by experienced psychiatrists or psychologists, and were reviewed by a clinical review board. The HC participants were recruited from Internet referrals and message boards at several universities, as well as through voluntary recruitment at the University of Tokyo Hospital. We used the Mini-International Neuropsychiatric Interview 29 to screen HC participants and to rule out psychiatric disorders; we also excluded HC participants with any first-degree relative(s) with psychotic disorders. As the UHR group was recruited from the helpseekers in clinical services who needed some clinical support and treatment for psychological symptoms, such as depression and anxiety, as well as subthreshold psychotic symptoms, we were able to rule out the possibility that the HC also fulfilled the inclusion criteria of the UHR group. Exclusion criteria for all groups included neurological illness, traumatic brain injury, a history of electroconvulsive therapy, a premorbid IQ of ≤70 on the Japanese Adult Reading Test, 30, 31 previous alcohol and illegal substance (e.g., cannabis) abuse or dependence, and definite diagnosis of autism spectrum disorders according to the DSM-IV criteria. A summary of inclusion and exclusion criteria for each group is shown in Table S2 .
After a complete explanation of the study, all participants gave written informed consent to a protocol that was approved by the ethics committee of the Faculty of Medicine, University of Tokyo (approval no. 630-9, 2226-5) in accordance with the Declaration of Helsinki.
Negative Syndrome Scale (PANSS; higher score means more severe symptoms) 32 at each measurement point. The equivalent doses of chlorpromazine, diazepam, biperiden, and imipramine were also calculated to show clinical backgrounds and courses in longitudinal measurements for the UHR and FEP groups. 33 
fNIRS instrument and measurement settings
We used a 52-channel fNIRS instrument (ETG-4000; Hitachi Medical Co., Tokyo, Japan) and a 160-s block-designed version (i.e., 30-s pre-task, 60-s task, and 70-s post-task) of the letter verbal fluency task as described previously, as shown in S1. 12, 21 The task period was divided into three sub-periods, and the instructed syllables changed every 20 s, to avoid silent moments. We recorded the total number of correct words as task performance. Previous studies showed that there was no significant correlation between the task performance and fNIRS signals. 12, 21 As the fNIRS algorithm variables and diagnosis system did not consider the task performance, 21 we did not use the task performance for the discrimination analysis in this study.
fNIRS algorithm variables
We synthesized signals from clustered channels in the Frontal Area (i.e., 11 channels in the frontal regions) and Temporal Area (i.e., 20 channels in the bilateral temporal regions) using principal component analysis of fNIRS waveforms, as done in the previous multisite study. 21 We excluded the data from two patients with ChSZ at baseline and one patient with FEP at follow up because there were fewer than six channels for each region available after filtering with the software and therefore did not support further analysis.
For each region, we calculated the Integral and Centroid values to quantitatively extract characteristics of the fNIRS waveforms that were found in the previous studies. 21 The Integral value represented the sum of the signal changes during the task period (Fig. 1a) . Higher value means greater activity associated with the cognitive task at each brain region. The threshold of the Integral value at the Frontal and Temporal Areas was set to 73 and 104, respectively. Participants were classified into the nonpatient group when the Integral value was more than the threshold (larger activity); otherwise, participants were classified into the patient group.
The Centroid value represents the activity timing and differentiates between psychosis spectrum disorders and MDD in patients manifesting depressive symptoms. 21 The Centroid value was defined as the time (s) when the area under the curve of the positive fNIRS signal change reached half of the total area for the whole task (Fig. 1b) . As relative fNIRS signal changes in this study were mostly seen during the task and post-task periods, a smaller value means more prompt response associated with the cognitive task at each brain region. The threshold of the Centroid value at the Frontal Area was 54 s (Fig. 1b) . Participants were classified into the psychosis spectrum group when the Centroid value was more than 54 (more delayed timing of activity); otherwise, participants were classified into the MDD group.
Statistical analysis
The cross-sectional group difference of fNIRS algorithm variables was tested using two-way repeatedmeasures analysis of covariance (ANCOVA) with Centroid and Integral values as dependent variables, Group (HC/UHR/FEP/ChSZ) as a between-subject factor, Region (Frontal/Temporal) as a withinsubject factor, and age at measurement and sex as covariates.
Discriminant analysis was performed in the ChSZ group to test whether the initial finding was replicable to the previous study; specifically, we ascertained whether participants would be classified to the patient group or the non-patient group using the Integral value and to the psychosis spectrum group or the MDD group using the Centroid value. Discriminant analysis was also performed in the UHR and FEP groups to determine whether they were distributed to the patient group using the Integral value or to the psychosis spectrum group using the Centroid value. Discriminant analysis was conducted for all participants, as well as those with clinically negative symptoms (File S1) in line with the existing algorithm. 21 In order to adjust the fNIRS algorithm variables for sex and age at measurement, we initially tested using a multivariate regression analysis that used the fNIRS variables as dependent variables, sex (male = 1, female = 0) and age as independent variables, and clinical diagnosis as a covariate. Then we used unstandardized regression coefficients, B, for sex and age in this analysis to subtract out the potential effect of sex and age. Since mean age in the previous multisite study was 43.9 years old and the sex ratio was almost 1:1, 21 we then corrected the age-and sex-effect on the fNIRS variables as follows:
Finally, we performed discrimination analysis using the modified fNIRS variables.
Longitudinal data were tested using three-way repeated measures ANCOVA for Time (baseline/follow up) as an additional within-subject factor and measurement interval as an additional covariate. In addition, intraclass correlation coefficients (ICC) were tested to confirm measurement stability between the two time-points. Discriminant analysis was also performed in the HC, UHR, and FEP groups using crude and modified fNIRS variables.
All analyses in this study were carried out using SPSS version 20.0J (IBM Inc., New York, USA). Significance level was set at P < 0.05, and Bonferroni corrections by area were applied to the correlation analysis (P < 0.025 = 0.05/2).
RESULTS
Demographic and clinical characteristics at the baseline measurement are shown in Table S1 .
Group differences in fNIRS algorithm variables at baseline
The fNIRS waveforms in each channel and group are shown in Figure 2 . The average waveforms in the Frontal and Temporal areas for each group are shown in Figure 1c ,d, respectively. For Integral value, there was a significant main effect of Group but not of Region, and the Group × Region interaction was not significant (Table S4 ). The FEP and ChSZ groups had smaller activity than the HC (P = 0.015 and P < 0.001, respectively). For Centroid value, there was no main effect for either Group or Region, but a significant Group × Region interaction was found (F = 3.0, P = 0.032, Table S4 ). Post-hoc Tukey tests showed that HC had significantly faster activation timing in the Frontal Area than the Temporal Area (P = 0.001). There was no significant relation between the fNIRS algorithm variables and any medication equivalent dose (chlorpromazine, biperiden, diazepam, or imipramine) in any of the groups.
Discrimination using fNIRS algorithm variables at baseline
Using the Integral value from the Frontal Area, 51.1% of UHR individuals (24/47), 63.3% of patients with FEP (19/30), and 62.5% of patients with ChSZ (20/32) were successfully classified to the patient group (Table 1) . This means that the remaining 48.9%, 36.7%, and 37.5% of the participants were classified to the non-patient group, respectively. Seventy percent of the HC (23/33) were classified to the non-patient group using the Integral value from the Frontal Area. The results of using the Integral value from the Temporal Area are shown in File S1.
Using the Centroid value from the Frontal Area, 68.8% of patients with ChSZ (22/32) were successfully classified to the psychosis spectrum group (Fig. 3c and Table 1 ). This means that the remaining were successfully classified into the psychosis spectrum group using the Centroid value from the Frontal Area (Fig. 3a,b , and Table 1 ).
The results for the participants who had clinically negative symptoms were similar to those for all participants (File S1).
Association between demographic characteristics and fNIRS algorithm variables
Younger HC had larger Integral and Centroid values in the Frontal Area (r = −0.48, P = 0.005; r = −0.42, P = 0.016, respectively). Other demographic and clinical characteristics were not associated with any fNIRS algorithm variable (P > 0.017). There was no significant correlation between the task performance and fNIRS algorithm variables in any areas for each group (P > 0.05).
Multiple regression analysis showed that Integral values from the Frontal Area were significantly affected by sex but not age (sex: B = −38, SE = 16, P = 0.016; age: B = −1.5, SE = 1.1, P = 0.16). However, Centroid values from the Frontal Area were significantly affected by both sex and age (sex: B = 57, SE = 22, P = 0.010; age: B = −4.1, SE = 1.5, P = 0.008).
Discrimination using modified fNIRS algorithm variables at baseline
Discrimination analysis using an Integral value from the Frontal Area modified by the parameters from the multivariate regression analyses showed that 63.8% (30/47) of the UHR group, 86.7% (26/30) of the FEP group, and 81.3% (26/32) of the ChSZ group were successfully classified to the patient group (Fig. 3d-f, (Fig. 3d-f , and Table 1 ).
All UHR individuals who later transited to psychosis (100%) were successfully classified to the psychosis spectrum group using the modified Centroid value from the Frontal Area at baseline, and 83.3% (5/6) were classified to the patient group using the modified Integral value from the Frontal Area at baseline (Fig. 3d ). Positive and negative predictive values for the UHR transition group were 0.28 (5/18) and 0.94 (15/16), respectively.
Longitudinal change in demographics and fNIRS algorithm variables
Results of longitudinal change in demographics and fNIRS algorithm variables are shown in Tables S3 Table S4 ), but a significant Group × Time interaction was found (F 2,81 = 3.6, P = 0.032). Within the Group × Time interaction, HC had significantly faster activation timing at baseline than at the 12-month follow up (P = 0.005); and the HC were faster than patients with FEP only at baseline (P = 0.018, Table S4 ). For the Integral value, there were significant main effects of Group (F 2, 81 = 8.6, P < 0.001) and Region (F 1, 81 = 6.4, P = 0.013), but not of Time (F 1, 81 = 2.3, P = 0.13). No significant interaction was found.
Intraclass correlation analysis showed that the HC had significant internal consistency in the Centroid value from the Frontal Area ( 
Discrimination analysis using the follow-up measurement
Using the crude Integral value from the Frontal Area, 58.8% of UHR individuals (20/34) and 65.0% of patients with FEP (13/20) were successfully classified to the patient group, whereas 57.6% of HC (19/33) were classified to the non-patient group. Using the modified Integral value from the Frontal Area, 82.4% (28/34) of individuals with UHR and 85.0% (17/20) of patients with FEP were successfully classified to the patient group. However, in the HC group, the classification rate did not improve much using the modified Integral values from the Frontal Area (Table 1) .
Using the crude Centroid value from the Frontal Area, 70.6% of UHR individuals (24/34) and 85.0% of patients with FEP (17/20) were successfully classified to the psychosis spectrum group (Table 1) . After adjusting for age and sex, 88.2% (30/34) and 95.0% (19/20) were successfully classified, respectively.
Internal consistency of fNIRS algorithm classification using the modified Integral and Centroid values at the Frontal Area in longitudinal measurements is summarized in Table S5 . For the Integral value, 58.8% of UHR individuals (20/34) and 75.0% of patients with FEP (15/20) were consistently classified to the patient group in baseline and follow-up measurements, whereas 45.5% of HC (15/33) were consistently classified to the non-patient group. For the Centroid value, 73.5% of UHR individuals (25/34) and 90.0% of patients with FEP (18/20) were consistently classified to the psychosis spectrum group in baseline and follow-up measurements. No UHR individual or patient with FEP was consistently classified to the MDD group and 66.7% (4/6) of UHR individuals who later transited to psychosis were consistently classified to the patient group and the psychosis spectrum group.
DISCUSSION
The present study investigated the reproducibility of an fNIRS for supplementary clinical examination using an independent dataset of patients with ChSZ, as well as its applicability to other clinical stages of psychotic disorders, such as UHR and FEP. Around two-thirds of patients with ChSZ were successfully classified to the patient group using the Integral value and to the psychosis spectrum group using the Centroid value. Two-thirds of UHR individuals and patients with FEP were also classified to the psychosis spectrum group, and these rates were maintained at the 12-month follow-up measurement. When the effects of age and sex were taken into account, over 80% of the UHR individuals and patients with FEP were classified to the psychosis spectrum group using the modified Centroid value. Additionally, over 80% of the patients with FEP and ChSZ were classified to the patient group using the modified Integral value. To the best of our knowledge, this is the first study to try to replicate a supplementary fNIRS measurement system for differential diagnosis and to show its applicability to people in the psychosis spectrum with various demographic characteristics and clinical stages. The advantage of our study is the utilization of the high temporal resolution and conciseness of the fNIRS technology.
This study showed that the modified Centroid value differentiated 83.0% of the UHR individuals and 83.3% of the patients with FEP into the psychosis spectrum group after taking into account age and sex, which is similar to the previous study that found that 85.5% of the patients with schizophrenia and BD were successfully classified. 21 The delayed timing of brain activity in schizophrenia has been shown repeatedly in fNIRS studies, but most patients with schizophrenia in these previous studies were in the chronic stage. 12, [14] [15] [16] [17] [18] As our present results only partly supported the reproducibility of the fNIRS algorithm variables, we here propose a new approach for the applicability to various clinical stages of psychotic disorders and demographic groups. The pathophysiology underlying delayed timing of activation in the psychosis spectrum group is unclear, but several explanations may be inferred from previous neurocognitive and neuroimaging studies that compare schizophrenia with MDD. A meta-analysis showed that people with psychosis spectrum had cognitive deficits predominantly in verbal manipulation, even before symptom onset. We also reported that smaller brain volume and function in the inferior frontal gyrus, related to verbal cognitive function, were evident in UHR individuals, which were not different from the patients with FEP and ChSZ. 4, 14, 24, 35 On the other hand, cognitive deficits in motor speed, working memory, and executive function were more prominent in firstepisode MDD. 36 Adolescence is prominent for cognitive development in accordance with brain maturation in the PFC and is also a peak period for the onset of psychosis and MDD. 10 Developmental alternation between the disease spectra may affect temporal brain activity during the verbal fluency task. Second, a recent meta-analysis has suggested altered resting state activity between schizophrenia and MDD in the ventromedial PFC. 37 Our previous fNIRS studies using an n-back working memory task and go/no-go task showed that decreased brain activity in the middle frontal gyrus region related to cognitive load was evident only in HC but not in patients with schizophrenia. 38, 39 The difference in resting brain activity between schizophrenia and MDD may have an effect on relative brain activity during the task period in this study.
Other than the effects of age, sex, and clinical stage, there are several reasons why some participants were not classified into the appropriate group. First, other demographic and clinical characteristics could affect activity in the PFC, such as duration of untreated psychosis, 40 illness duration, 40 and participants' present level of functioning. 17, 24 Second, the participants in this study were clinically diagnosed as having schizophrenia spectrum disorders, and no patient was diagnosed as having BD. Because the threshold of the Centroid value was set to differentiate between patients with MDD and psychotic disorders (i.e., schizophrenia and BD), this may affect accuracy. Third, in terms of the Integral value, the intensity of brain activity shows considerable variation within the HC group. 41, 42 In particular, the Integral value at the Frontal Area and its classification had poor consistency between measurements in the HC. Also, the classification did not improve after modification by sex and age compared to other fNIRS variables. Finally, we applied a linear fitting method using the results of a multivariate linear regression with only sex and age as independent variables to the correction of the fNIRS algorithm. The present study showed a relatively poor discrimination rate for the HC, possibly because the linear fitting correction had a relatively narrow age range compared to the previous study, 21 which might decrease the classification rate. Using non-linear fitting, such as curvilinear models, and considering age by sex interactions in large numbers of participants from various age groups, could improve the classification rate of the fNIRS algorithm. Future studies should establish better diagnostic neuroimaging tools by combining additional demographic and clinical characteristics with advanced statistical models.
Follow-up measurements also had high discrimination rates irrespective of the lack of high internal consistency of the fNIRS algorithm variables in the patient groups. As fNIRS activity in the PFC was affected by clinical stages and present functioning, 17, 24 and possibly by the illness course in psychosis, such as progressive brain pathology in schizophrenia, 6 the fNIRS algorithm variables themselves could have partially state-dependent variance, especially in the UHR and FEP groups. Nonetheless, a psychosis trait could also affect the fNIRS algorithm variables to retain a high discrimination rate in the follow-up measurements.
The preliminary findings of this study imply that the fNIRS algorithm variables may be applicable to a potential biomarker for the prediction of the nontransition to psychosis. Previous MRI studies have proposed volume reduction in specific brain regions 3 and the use of a support vector machine 7 as one candidate biological marker for predicting the transition to psychosis. One strength of this fNIRS algorithm is that the approach intended to differentiate between psychosis spectrum disorders and MDD, while the approach often used in MRI studies is intended to differentiate between UHR individuals who later transition to psychosis and those who do not. We also showed that the classification rate was not significantly different based on the presence or absence of clinically negative symptoms. Long-term clinical follow-up studies have suggested that most UHR individuals receive comorbid diagnoses of MDD and/or anxiety disorders, regardless of whether or not they have transitioned to psychosis. 43 The fNIRS computational approach could also be a biological marker for decision-making concerning differential diagnosis and treatment options in UHR individuals. However, future studies with multicenter recruitment and long-term longitudinal measurements should be conducted to enable more participants who later transition to psychosis to be tested. This study had methodological limitations. First, the number of participants in this study was small for aiming to offer a diagnostic tool. In addition, we did not obtain data from patients with MDD or BD, which could have affected classification rates and the fNIRS variable correction. Therefore, the results are still preliminary for clinical application. Future studies are needed to investigate whether people in the psychotic spectrum could be differentiated from young people with MDD, as it is difficult to determine definite diagnoses with one cross-sectional assessment. Second, the corrected values of the fNIRS variables should be defined using more participants with greater diversity in demographic characteristics, clinical stages, and disease spectrum groups. Third, because we adopted a naturalistic study design, most of the patients in our study were receiving medical care, including medication. We previously reviewed that medication has little effect on fNIRS signals as tested in this study. 12 However, potential effects of medication should be examined. Finally, potential effect of the non-brain factors of the fNIRS algorithm variables may be considered, because the fNIRS signals were detected by the near-infrared light passing through the cortex as well as the scalp and skull. Thus, autonomic response can affect the results. A new method to exclude the signals from outside the brain should be used and autonomic responses, such as pulse rate or blood pressure, should also be simultaneously examined in future studies.
In conclusion, the present study demonstrates the possibility that the fNIRS for supplementary clinical examination is useful for differentiating various clinical stages of the psychosis spectrum from MDD. Compared to MRI, fNIRS offers an easier way to measure hemodynamic response without a restricted position over a long period and, thus, could be more suitable for people with mental illness. Future studies should be done to further improve the accuracy of supplementary diagnostic systems for clinical use by, for example, combining the high spatial resolution advantage of MRI with the high temporal resolution of fNIRS. The approved protocol of fNIRS as supplementary examination for diagnosis does not control age and sex, and this study revealed the need for adjustment of age and sex for accurate discrimination. Future multisite studies may propose the revision of the protocol to the regulatory agency. 
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